1. Scrip
  2. >>Therapy Areas

ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno

 
• By Mandy Jackson

Kite reported interim results for KTE-C19 from the ZUMA-1 study that showed efficacy consistent with earlier results without the deaths from neurotoxicity that have plagued Juno, but Juno’s latest CAR-T offering may carry fewer safety concerns.

The American Society of Hematology annual meeting helped set the stage for what could be the first chimeric antigen receptor T-cell (CAR-T) therapies approved in the US with Kite Pharma Inc. maintaining its spot as a leader in the field, while Juno Therapeutics Inc. continues to face questions about safety.

Kite’s latest data from the ZUMA-1 clinical trial, which is expected to support US FDA approval of the CAR-T therapy axicabtagene ciloleucel (KTE-C19), showed consistent efficacy in aggressive non-Hodgkin lymphoma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.